Terms: = Skin cancer AND KRAS, C-K-RAS, 3845, P01116, NS3, KI-RAS, KRAS2, K-RAS4A, K-RAS2A, K-RAS4B, KRAS1, K-RAS2B, RASK2 AND Treatment
236 results:
1. FOXM1 promote the growth and metastasis of uveal melanoma cells by regulating CDK2 expression.
Bai X; Li S; Luo Y
Int Ophthalmol; 2024 Feb; 44(1):55. PubMed ID: 38342795
[TBL] [Abstract] [Full Text] [Related]
2. A Phase 1b/2a Study of GC1118 with 5-Fluorouracil, Leucovorin and Irinotecan (FOLFIRI) in Patients with Recurrent or Metastatic Colorectal cancer.
Lee KW; Han SW; Kim TW; Ahn JB; Baek JY; Cho SH; Lee H; Kim JW; Kim JW; Kim TY; Hong YS; Beom SH; Cha Y; Choi Y; Kim S; Bang YJ
Cancer Res Treat; 2024 Apr; 56(2):590-601. PubMed ID: 38062706
[TBL] [Abstract] [Full Text] [Related]
3. First-in-human study of naporafenib (LXH254) with or without spartalizumab in adult patients with advanced solid tumors harboring MAPK signaling pathway alterations.
Janku F; Kim TM; Iyer G; Spreafico A; Elez E; de Jonge M; Yamamoto N; van der Wekken AJ; Ascierto PA; Maur M; Marmé F; Kiladjian JJ; Basu S; Baffert F; Buigues A; Chen C; Cooke V; Giorgetti E; Kim J; McCarthy F; Moschetta M; Dummer R
Eur J Cancer; 2024 Jan; 196():113458. PubMed ID: 38039779
[TBL] [Abstract] [Full Text] [Related]
4. Sotorasib plus Panitumumab in Refractory Colorectal cancer with Mutated
Fakih MG; Salvatore L; Esaki T; Modest DP; Lopez-Bravo DP; Taieb J; Karamouzis MV; Ruiz-Garcia E; Kim TW; Kuboki Y; Meriggi F; Cunningham D; Yeh KH; Chan E; Chao J; Saportas Y; Tran Q; Cremolini C; Pietrantonio F
N Engl J Med; 2023 Dec; 389(23):2125-2139. PubMed ID: 37870968
[TBL] [Abstract] [Full Text] [Related]
5. Plasma Cetuximab Concentrations Correlate With Survival in Patients With Advanced kras Wild Type Colorectal cancer.
Jiang DM; Parshad S; Zhan L; Sim HW; Siu LL; Liu G; Shapiro JD; Price TJ; Jonker DJ; Karapetis CS; Strickland AH; Zhang W; Jeffery M; Tu D; Ng S; Sabesan S; Shannon J; Townsend A; O'Callaghan CJ; Chen EX
Clin Colorectal Cancer; 2023 Dec; 22(4):457-463. PubMed ID: 37704538
[TBL] [Abstract] [Full Text] [Related]
6. Primary mucosal melanomas of the urogenital tract: a clinical, pathological, and genetic nationwide survey of Danish patients 1990-2019.
Znaider VK; Mikkelsen LH; Jensen CFS; Sønksen J; Heegaard S
Scand J Urol; 2023 Aug; 58():52-59. PubMed ID: 37635444
[TBL] [Abstract] [Full Text] [Related]
7. Prognostic biomarkers for survival in mucosal melanoma.
Thierauf JC; Kaluziak ST; Codd E; Dybel SN; Jobbagy S; Purohit R; Farahani AA; Dedeilia A; Naranbhai V; Hoang MP; Fisch AS; Ritterhouse L; Boland GM; Lennerz JK; Iafrate AJ
Pigment Cell Melanoma Res; 2023 Sep; 36(5):378-387. PubMed ID: 37390098
[TBL] [Abstract] [Full Text] [Related]
8. Multimodal treatment and immune checkpoint inhibition in sinonasal mucosal melanoma: real-world data of a retrospective, single-center study.
Scherzad A; Stöth M; Meyer TJ; Haug L; Gehrke T; Schilling B; Meierjohann S; Scheich M; Hagen R; Gesierich A; Hackenberg S
Eur Arch Otorhinolaryngol; 2023 Sep; 280(9):4215-4223. PubMed ID: 37272953
[TBL] [Abstract] [Full Text] [Related]
9. MicroRNA-708 emerges as a potential candidate to target undruggable NRAS.
Pang JM; Chien PC; Kao MC; Chiu PY; Chen PX; Hsu YL; Liu C; Liang X; Lin KT
PLoS One; 2023; 18(4):e0284744. PubMed ID: 37083947
[TBL] [Abstract] [Full Text] [Related]
10. Antibodies against endogenous retroviruses promote lung cancer immunotherapy.
Ng KW; Boumelha J; Enfield KSS; Almagro J; Cha H; Pich O; Karasaki T; Moore DA; Salgado R; Sivakumar M; Young G; Molina-Arcas M; de Carné Trécesson S; Anastasiou P; Fendler A; Au L; Shepherd STC; Martínez-Ruiz C; Puttick C; Black JRM; Watkins TBK; Kim H; Shim S; Faulkner N; Attig J; Veeriah S; Magno N; Ward S; Frankell AM; Al Bakir M; Lim EL; Hill MS; Wilson GA; Cook DE; Birkbak NJ; Behrens A; Yousaf N; Popat S; Hackshaw A; ; ; Hiley CT; Litchfield K; McGranahan N; Jamal-Hanjani M; Larkin J; Lee SH; Turajlic S; Swanton C; Downward J; Kassiotis G
Nature; 2023 Apr; 616(7957):563-573. PubMed ID: 37046094
[TBL] [Abstract] [Full Text] [Related]
11. Deep and lasting response and acquired resistance to BRAFV600E targeting in a low-grade ovarian cancer patient.
Anchisi S; Wolfer A; Bisig B; Missiglia E; Tiab A; Kamel EM; Michielin O; Coukos G; Homicsko K
Cancer Biol Ther; 2023 Dec; 24(1):2193116. PubMed ID: 36967525
[TBL] [Abstract] [Full Text] [Related]
12. Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in
de Braud F; Dooms C; Heist RS; Lebbe C; Wermke M; Gazzah A; Schadendorf D; Rutkowski P; Wolf J; Ascierto PA; Gil-Bazo I; Kato S; Wolodarski M; McKean M; Muñoz Couselo E; Sebastian M; Santoro A; Cooke V; Manganelli L; Wan K; Gaur A; Kim J; Caponigro G; Couillebault XM; Evans H; Campbell CD; Basu S; Moschetta M; Daud A
J Clin Oncol; 2023 May; 41(14):2651-2660. PubMed ID: 36947734
[TBL] [Abstract] [Full Text] [Related]
13. Adverse reactions and efficacy of camrelizumab in patients with lung adenocarcinoma with high PD-L1 expression: A case report.
Wei T; Wang Z; Liu X
Medicine (Baltimore); 2023 Feb; 102(7):e32731. PubMed ID: 36800626
[TBL] [Abstract] [Full Text] [Related]
14. MARCO is a potential prognostic and immunotherapy biomarker.
Dong Q; Zhang S; Zhang H; Sun J; Lu J; Wang G; Wang X
Int Immunopharmacol; 2023 Mar; 116():109783. PubMed ID: 36773567
[TBL] [Abstract] [Full Text] [Related]
15. Compound clear cell sarcoma with EWSR1::CREM fusion.
Li P; Busam K
J Cutan Pathol; 2023 Dec; 50(12):1065-1069. PubMed ID: 36640048
[TBL] [Abstract] [Full Text] [Related]
16. Molecular underpinnings of exceptional response in primary malignant melanoma of the esophagus to anti-PD-1 monotherapy.
Dai J; Bai X; Gao X; Tang L; Chen Y; Sun L; Wei X; Li C; Qi Z; Kong Y; Cui C; Chi Z; Sheng X; Xu Z; Lian B; Li S; Yan X; Tang B; Zhou L; Wang X; Xia X; Guo J; Mao L; Si L
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36593066
[TBL] [Abstract] [Full Text] [Related]
17. Circulating tumor DNA is a prognostic biomarker in metastatic melanoma patients treated with chemoimmunotherapy and BRAF inhibitor.
Mattila KE; Mäkelä S; Kytölä S; Andersson E; Vihinen P; Ramadan S; Skyttä T; Tiainen L; Vuoristo MS; Tyynelä-Korhonen K; Koivunen J; Kohtamäki L; Aittomäki K; Hernberg M
Acta Oncol; 2022 Oct; 61(10):1263-1267. PubMed ID: 36307938
[TBL] [Abstract] [Full Text] [Related]
18. A rapidly growing cutaneous malignant glomus tumor with a CCND3 mutation.
Kitz R; Leung O; Royer M
J Cutan Pathol; 2023 Feb; 50(2):113-117. PubMed ID: 36059094
[TBL] [Abstract] [Full Text] [Related]
19. Sebaceous nevus of Jadassohn: review and clinical-surgical approach.
Neto MPDS; Assis BR; Andrade GR
An Bras Dermatol; 2022; 97(5):628-636. PubMed ID: 35863943
[TBL] [Abstract] [Full Text] [Related]
20. Acute generalized exanthematous pustulosis caused by gemcitabine after nivolumab in metastatic lung adenocarcinoma followed by a dramatic tumor response: A case report.
Magdelaine P; Costantini A; Fabre L; Giroux-Leprieur E
Thorac Cancer; 2022 Jul; 13(13):1994-1997. PubMed ID: 35615894
[TBL] [Abstract] [Full Text] [Related]
[Next]